Treatment and outcome of autoimmune hepatitis: Audit of 28 <scp>UK</scp> centres
Victoria Gordon(University Hospitals Coventry and Warwickshire NHS Trust), Dermot Gleeson(Sheffield Teaching Hospitals NHS Foundation Trust), George Abouda, Selena Dixon(Airedale NHS Foundation Trust), Sushma Saksena(Royal London Hospital), Stavroula Pelitari(University Hospitals Coventry and Warwickshire NHS Trust), Andrew D. Yeoman(Aneurin Bevan University Health Board), Annell Prosser(Singleton Hospital), James Day(Addenbrooke's Hospital), Claire Hardie(Freeman Hospital), Ratul Adhikary(Calderdale Royal Hospital), Martin Prince(King's College London), Alick Nkhoma(University Hospitals of North Midlands NHS Trust), Victoria Appleby(Bradford Teaching Hospitals NHS Foundation Trust), John M. Hutchinson(University of Aberdeen), David Elphick(Chesterfield Royal Hospital), Toby Delahooke(University Hospitals of Leicester NHS Trust), Andrew Nelson(University of California, San Francisco), Guruprasad P. Aithal(NIHR Nottingham Digestive Diseases Biomedical Research Unit), Deven Vani(Mid Yorkshire Hospitals NHS Trust), Rebecca Jones(St James's University Hospital), Barbara Hoeroldt(The Rotherham NHS Foundation Trust), Faisal Khan(Doncaster Royal Infirmary), Michael A. Heneghan(King's College Hospital NHS Foundation Trust), Jane Metcalf(University Hospital of North Tees), V Sathyanarayana(Barnsley Hospital), Patricia Hooper(Royal Derby Hospital), Debasish Das
Cited by 17
Related Papers
Global prevalence of dementia: a Delphi consensus study
|The Lancet|2005|5.3k
Obeticholic acid for the treatment of non-alcoholic steatohepatitis: interim analysis from a multicentre, randomised, placebo-controlled phase 3 trial
|The Lancet|2019|1.2k
HLA-B*5701 genotype is a major determinant of drug-induced liver injury due to flucloxacillin
|Nature Genetics|2009|1.1k
Elafibranor, an Agonist of the Peroxisome Proliferator−Activated Receptor−α and −δ, Induces Resolution of Nonalcoholic Steatohepatitis Without Fibrosis Worsening
|Gastroenterology|2016|1k
Guidelines on the management of ascites in cirrhosis
|Gut|2020|661